Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05416164

DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
595 (estimated)
Sponsor
The Netherlands Cancer Institute · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study evaluates whether radiotherapy can safely be omitted in breast cancer patients with T1-2N0 tumors who achieve a pathologic complete response after neoadjuvant systemic therapy and breast-conserving surgery

Detailed description

The proportion of women diagnosed with breast cancer who are treated with neoadjuvant systemic therapy is increasing. Depending on the subtype, 10-75% of these patients will have a pathologic complete response. Currently breast conserving surgery with pathologic complete response is followed by radiotherapy. In this patient group risk of local recurrence is low, but radiotherapy may cause considerable morbidity. The aim of this study is to investigate whether omitting radiotherapy is safe for patients with a node-negative breast tumor \<5cm treated with neoadjuvant systemic therapy and breast conserving surgery who achieve a pathologic complete response

Conditions

Interventions

TypeNameDescription
RADIATIONOmission of radiotherapyOmission of radiotherapy

Timeline

Start date
2022-10-07
Primary completion
2032-05-01
Completion
2037-05-01
First posted
2022-06-13
Last updated
2025-03-26

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT05416164. Inclusion in this directory is not an endorsement.